List of Excipients in Branded Drug METHADOSE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SpecGx LLC	METHADOSE	methadone hydrochloride	0406-0527	ANHYDROUS CITRIC ACID
SpecGx LLC	METHADOSE	methadone hydrochloride	0406-0527	D&C RED NO. 33
SpecGx LLC	METHADOSE	methadone hydrochloride	0406-0527	FD&C RED NO. 40
SpecGx LLC	METHADOSE	methadone hydrochloride	0406-0527	METHYLPARABEN
SpecGx LLC	METHADOSE	methadone hydrochloride	0406-0527	POLOXAMER 407

Generic Drugs Containing METHADOSE

Company	Ingredient	NDC	Excipient
SpecGx LLC	methadone hydrochloride	0406-0540	CELLULOSE, MICROCRYSTALLINE
SpecGx LLC	methadone hydrochloride	0406-0540	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
SpecGx LLC	methadone hydrochloride	0406-0540	MAGNESIUM STEARATE
SpecGx LLC	methadone hydrochloride	0406-0540	SILICON DIOXIDE
SpecGx LLC	methadone hydrochloride	0406-0540	STARCH, CORN

What are the Most Frequently-Used Excipients in METHADOSE?

# Of NDCs	Excipient

Methadose Excipient Strategy and Commercial Opportunities

Last updated: October 9, 2026

Methadose is a methadone hydrochloride product whose commercial differentiation depends more on formulation execution, supply reliability, dosing safety, and regulatory compliance than on active-ingredient exclusivity. The strongest excipient opportunities are alcohol-free and sugar-reduced liquids, taste-masked oral solutions, unit-dose packaging, high-stability formulations, and excipient systems designed for controlled dispensing in opioid treatment programs.

What is Methadose and how is it regulated?

Methadose is a brand of methadone hydrochloride, an opioid agonist available in oral dosage forms. Methadone is used for opioid use disorder treatment under regulated opioid treatment programs and for selected pain indications under prescribing controls.[1]

Attribute	Methadose
Active ingredient	Methadone hydrochloride
Main commercial form	Oral concentrate, commonly 10 mg/mL
Pharmacologic class	Opioid agonist
U.S. controlled-substance schedule	Schedule II
Primary institutional market	Opioid treatment programs, hospitals, specialty pharmacies
Key formulation issue	Accurate measurement of a high-potency liquid
Key commercial issue	Controlled dispensing, diversion prevention, and supply continuity
Principal regulatory authority	FDA, DEA, and SAMHSA for opioid treatment programs

Methadone has been marketed for decades. Its active ingredient is not protected by a modern composition-of-matter patent, and Methadose competes in a market where generic methadone products and alternate dosage forms are available.

What excipients are used in Methadose?

The Methadose oral concentrate label identifies excipients that support acidity control, preservation, palatability, and liquid stability. Public labeling should be used as the controlling source for any product-specific composition because inactive ingredients can differ by strength, dosage form, manufacturer, and manufacturing site.[2]

Methadose oral concentrate excipient profile

The reported excipient system for the oral concentrate includes:

Excipient or component	Likely formulation function	Commercial relevance
Purified water	Vehicle	Determines solubility, microbial control, and container compatibility
Citric acid	Acidulant and pH adjuster	Supports chemical stability and flavor balance
Sodium benzoate	Preservative	Controls microbial growth in a multidose liquid
Sucrose	Sweetener and mouthfeel modifier	Improves palatability but limits use in some patients
Flavoring system	Taste masking	Reduces aversion to methadone’s bitter taste
Methadone hydrochloride	Active pharmaceutical ingredient	Highly water-soluble salt used in the liquid product

The formulation is commercially practical because methadone hydrochloride dissolves readily in aqueous systems. The excipient challenge is not solubilization. It is maintaining dose uniformity, acceptable taste, preservative performance, chemical stability, and dispensing accuracy across repeated use.

Why the excipient system matters

Methadone has a narrow therapeutic margin in some clinical settings. A liquid formulation must deliver a consistent dose after storage, repeated opening, dilution, and handling. Excipient selection therefore affects:

• assay and content uniformity;
• pH stability;
• preservative effectiveness;
• precipitation risk;
• taste and patient acceptance;
• container compatibility;
• dosing-device accuracy;
• microbial control after opening;
• stability under pharmacy and clinic conditions.

The commercial value of an improved excipient system is linked to risk reduction rather than a new therapeutic mechanism.

What excipient strategies could improve Methadose?

Can an alcohol-free Methadose formulation create commercial value?

Yes. An alcohol-free formulation could address concerns involving pediatric exposure, alcohol-sensitive patients, institutional policies, and repeated administration. The formulation would need to preserve methadone solubility and chemical stability without relying on ethanol as a cosolvent or preservative component.

Potential approaches include:

• optimized aqueous pH control;
• alternative preservative systems;
• chelating agents where justified by degradation pathways;
• improved container closure systems;
• single-dose or unit-dose packaging;
• antimicrobial manufacturing controls that reduce reliance on preservatives.

An alcohol-free claim would have commercial value if supported by comparative stability, preservative-effectiveness testing, and a clear clinical or institutional use case.

Can sugar-free Methadose compete with the existing liquid?

A sugar-free product could target patients with diabetes, metabolic disease, dental-health concerns, or long-term treatment needs. Removing sucrose can impair taste and mouthfeel, so the replacement system would require a compatible high-intensity sweetener, bulk sweetener, or polymer-based mouthfeel modifier.

Potential excipient candidates include:

• sucralose;
• acesulfame potassium;
• saccharin derivatives;
• polyols, subject to gastrointestinal tolerability;
• glycerin or sorbitol for mouthfeel;
• flavor modulators that suppress bitterness.

A sugar-free product would face three technical constraints. First, sweetener changes can alter pH and preservative performance. Second, methadone’s bitter and medicinal taste may remain detectable despite high-intensity sweeteners. Third, any new flavor system would require palatability testing in the intended patient population.

What taste-masking technologies are relevant?

Taste masking is a direct commercial opportunity because methadone can produce a strong bitter or medicinal taste. Conventional flavor addition may be insufficient at a 10 mg/mL concentration.

Relevant technologies include:

1. Ion-exchange resin complexes.
2. Polymer coating of drug particles.
3. Cyclodextrin complexation.
4. Lipid or emulsion-based taste barriers.
5. pH-mediated reduction of free drug in the oral cavity.
6. Multiparticulate or granulated oral dosage forms.
7. Flavor systems that combine sweetness, cooling, and bitterness suppression.

For a highly soluble drug, resin complexation and polymer barriers may be more effective than simple coating. The main development risk is delayed or incomplete drug release after swallowing. Any taste-masking system must demonstrate rapid release under gastrointestinal conditions while limiting release in saliva.

Are preservative alternatives commercially attractive?

Methadose oral concentrate uses a preservative system suitable for multidose packaging. Alternative systems could create value if they improve tolerability, reduce preservative exposure, or support a preservative-free unit-dose product.

Potential alternatives include:

• potassium sorbate;
• parabens;
• benzoate-free systems;
• antimicrobial packaging;
• single-dose ampoules or cups;
• aseptic filling with validated container closure integrity.

A preservative change is not automatically an improvement. Preservative effectiveness testing, degradation analysis, extractables and leachables testing, and in-use stability are required. For clinic-dispensed products, unit-dose packaging may provide greater value than a new preservative alone.

What dosage forms offer the best commercial opportunity?

Oral concentrate

The oral concentrate is the most direct platform for excipient innovation. Opportunities include:

• alcohol-free concentrate;
• sugar-free concentrate;
• improved flavor and taste masking;
• lower-volume high-concentration product;
• multidose bottle with integrated dosing adapter;
• unit-dose oral cups;
• tamper-evident packaging;
• color or marker systems that reduce dispensing errors.

The principal risk is dosing error. Higher concentration reduces administration volume but increases the consequences of a measurement mistake. Commercial development should therefore pair the formulation with a calibrated oral syringe, dosing cup, or clinic-specific dispensing system.

Ready-to-use oral solution

A ready-to-use solution could reduce pharmacy dilution and clinic handling. It would be attractive to opioid treatment programs that need consistent, rapid administration with fewer compounding steps.

The product would require:

• robust in-use stability;
• clear concentration labeling;
• container closure compatibility;
• resistance to accidental substitution;
• validated dosing devices;
• packaging appropriate for controlled-substance inventory management.

Dispersible or soluble tablets

Methadone tablets can support controlled dispensing and lower shipping volume. A rapidly dispersible tablet may be suitable for supervised administration, but it must avoid dose loss, incomplete dispersion, and manipulation concerns.

Relevant excipient technologies include:

• superdisintegrants;
• directly compressible fillers;
• wetting agents;
• taste-masking polymers;
• effervescent systems;
• low-dusting tablet compositions.

A dispersible tablet could compete with liquid products in clinics if administration is simple and the dosage range is flexible.

Unit-dose solid or liquid products

Unit-dose packaging may offer the clearest institutional value. It can improve inventory control, reduce cross-contamination risk, and support observed dosing. The tradeoff is higher packaging cost and greater manufacturing complexity.

What patents protect Methadose?

Methadose is not primarily protected by a contemporary patent estate. Methadone hydrochloride is an old active ingredient, and the commercial product is generally exposed to generic competition.

Protection category	Methadose position
Active-ingredient patent	No meaningful current composition-of-matter protection
Core oral-solution patent	No widely recognized patent barrier comparable to a new chemical entity
Formulation patents	Possible for specific improved formulations, but must be assessed claim by claim
Method-of-use patents	Limited commercial blocking power because methadone uses are long established
Orange Book patent strategy	Product-specific listings, if any, require current FDA Orange Book verification
Regulatory exclusivity	No expected new-drug exclusivity for an established methadone product
Generic entry barrier	Primarily manufacturing, supply, controlled-substance compliance, and formulation execution

An improved excipient formulation could generate patent value only if it contains a non-obvious combination with demonstrated technical effects. Broad claims to methadone, water, sweetener, flavor, or preservative would face substantial validity and prior-art risk.

What is the Orange Book and FDA status of Methadose?

The FDA Orange Book identifies approved drug products and, where applicable, patent and exclusivity information.[3] Methadose should be evaluated by its specific NDA, dosage form, strength, and marketing status rather than by the brand name alone.

For commercial diligence, the relevant checks are:

• whether the Methadose product is currently listed as marketed;
• whether the product is listed under an NDA or ANDA;
• whether patents are listed for the specific product;
• whether therapeutic-equivalence codes apply to competing products;
• whether any product has a discontinued or withdrawn status;
• whether the same sponsor markets related methadone dosage forms.

Because methadone products have changed manufacturers and labels over time, historical approval information should not be treated as evidence of current commercial availability.

When does Methadose lose exclusivity?

Methadose has no conventional near-term loss-of-exclusivity event comparable to a patented branded medicine. The relevant exclusivity has already expired for the old active ingredient and established dosage forms.

Commercial entry is therefore governed by:

• ANDA approval;
• bioequivalence or applicable performance requirements;
• controlled-substance manufacturing authorization;
• DEA registration and quota requirements;
• supply of pharmaceutical-grade methadone;
• state pharmacy and opioid-treatment-program rules;
• ability to obtain clinic and institutional contracts.

A competitor does not need to wait for a major patent expiry if it can obtain FDA approval and meet controlled-substance requirements.

Which companies are challenging or competing with Methadose?

Competition comes from manufacturers of methadone hydrochloride oral solutions, tablets, and other approved dosage forms rather than from a single litigation-driven challenger. The competitive field can include:

• branded or authorized generic methadone products;
• ANDA-approved oral solutions;
• methadone tablets;
• clinic-compounded or pharmacy-dispensed formulations where permitted;
• alternative opioid-treatment products, including buprenorphine products.

The most relevant competitors are those with reliable supply, established opioid-treatment-program relationships, and dosage forms that fit observed-dosing workflows.

Public data do not reliably isolate Methadose revenue from broader methadone sales. Revenue exposure should therefore be estimated using product-level sales data, institutional contracts, prescription volume, and opioid-treatment-program purchasing rather than brand-level assumptions.

What patent litigation and Paragraph IV risks exist?

Methadose is more exposed to generic substitution and abbreviated-approval competition than to patent litigation. A Paragraph IV challenge would be commercially relevant only if a current, enforceable patent were listed for a specific Methadose formulation or delivery system.

For an improved Methadose product, the main litigation risks would involve:

• obviousness of the excipient combination;
• anticipation by older methadone solutions;
• inadequate written description;
• lack of demonstrated unexpected results;
• non-infringement based on different preservative or sweetener systems;
• invalidity of narrow formulation claims.

Formulation patents are stronger when they connect a defined excipient range to a measured technical result, such as improved stability, reduced precipitation, enhanced taste masking, or preservative effectiveness at a lower concentration.

How strong is the patent estate for an improved Methadose formulation?

A conventional Methadose excipient estate would likely be weak if it covers only routine ingredients. A stronger estate would combine composition, manufacturing, packaging, and use claims.

Potential patent claim architecture

Claim type	Commercial purpose
Liquid composition	Protects defined methadone, pH, preservative, sweetener, and flavor ranges
Taste-masked composition	Protects resin, polymer, cyclodextrin, or multiparticulate technology
Unit-dose package	Protects a controlled-dispensing presentation
Dosing system	Protects bottle adapter, syringe, cup, or clinic dispensing configuration
Stability claim	Protects an unexpectedly stable formulation over a defined period
Manufacturing process	Protects mixing order, temperature, filtration, or filling conditions
Method of administration	Protects supervised dosing using the particular presentation

The strongest commercial strategy would avoid reliance on a single formulation patent. A layered portfolio could combine a core composition patent with packaging, dosing-device, and manufacturing-process claims.

What manufacturing and supply barriers protect the business?

The main barriers are operational rather than legal. Methadone is a controlled substance, so a new manufacturer must manage:

• DEA registration;
• production quotas;
• controlled-substance security;
• inventory reconciliation;
• diversion controls;
• validated cleaning and containment;
• specialized serialization and shipment procedures;
• qualified API supply;
• regulatory inspections;
• clinic and wholesaler distribution requirements.

Excipient supply also matters. Sodium benzoate, sweeteners, flavors, polymers, and packaging components should have qualified alternate suppliers. Flavor systems can create hidden single-source risk because a replacement flavor may alter dissolution, preservative performance, or label claims.

What licensing deals could support a Methadose opportunity?

Licensing opportunities are most credible in four areas:

1. Taste-masking technology licensed from a specialty excipient company.
2. Dosing and packaging systems licensed from a medical-device supplier.
3. Alcohol-free or sugar-free formulation technology licensed from a drug-delivery developer.
4. Contract manufacturing or controlled-substance distribution arrangements with an established methadone manufacturer.

A license should address ownership of formulation improvements, regulatory filing rights, supply obligations, audit rights, change-control procedures, and responsibility for controlled-substance compliance. Royalty economics are likely to be constrained by the generic nature of methadone unless the licensed technology produces a measurable institutional benefit.

What generic launch scenarios exist for Methadose?

Scenario	Market effect	Principal success factor
Low-cost oral-solution entrant	Price pressure	Reliable API and high-volume manufacturing
Alcohol-free entrant	Segment differentiation	Stability and tolerability data
Sugar-free entrant	Patient and institutional niche	Palatability and payer acceptance
Unit-dose clinic product	Workflow differentiation	Packaging economics and supply reliability
Taste-masked product	Patient acceptance	Demonstrated reduction in aversive taste
Dispersible tablet	Operational substitution	Rapid dispersion and dose flexibility
Supply-disruption entrant	Contract capture	Fast regulatory and manufacturing execution

The most defensible commercial position is likely a differentiated institutional product rather than an undifferentiated methadone solution.

Key Takeaways

• Methadose’s opportunity is formulation and delivery differentiation, not active-ingredient exclusivity.
• The principal oral-concentrate excipients are water, citric acid, sodium benzoate, sucrose, and flavoring components, subject to product-specific labeling.
• Alcohol-free, sugar-free, taste-masked, and unit-dose presentations offer the clearest commercial pathways.
• Methadone’s controlled-substance status creates meaningful manufacturing, distribution, and compliance barriers.
• A conventional excipient patent would face substantial prior-art and obviousness risk.
• A stronger portfolio would combine formulation, packaging, dosing-device, manufacturing, and stability claims.
• Generic competition can enter without waiting for a major patent expiry if FDA, DEA, and supply requirements are satisfied.
• Revenue exposure should be evaluated through institutional contracts and methadone-market data because Methadose-specific revenue is not consistently disclosed publicly.

FAQs

Is Methadose the same as methadone?

Methadose is a branded methadone hydrochloride product. Methadone is the active ingredient, while Methadose refers to a particular marketed product and presentation.

Does Methadose contain sugar?

The oral concentrate labeling identifies sucrose as an inactive ingredient. A sugar-free competitor would require a different formulation and separate FDA approval.

Can Methadose be reformulated without sodium benzoate?

Potentially, but removing or replacing sodium benzoate would require new stability, preservative-effectiveness, compatibility, and regulatory-supporting data.

Is methadone suitable for a 505(b)(2) reformulation strategy?

A 505(b)(2) pathway may be relevant for certain new dosage forms, delivery systems, or formulation changes, depending on the proposed product and FDA reference-product framework. The regulatory strategy would need to match the specific formulation difference.

What is the best commercial excipient opportunity for Methadose?

The strongest opportunity is a clinically and operationally differentiated product combining improved taste, sugar-free or alcohol-free composition, accurate dosing, and unit-dose or controlled-dispensing packaging.

References

1. U.S. Food and Drug Administration. (2024). Methadone hydrochloride prescribing information. FDA. https://www.fda.gov
2. DailyMed. (n.d.). Methadose: Methadone hydrochloride oral concentrate label. National Library of Medicine. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Drug Enforcement Administration. (2024). Controlled substances act. U.S. Department of Justice. https://www.dea.gov
5. Substance Abuse and Mental Health Services Administration. (2024). Opioid treatment program regulations and guidance. U.S. Department of Health and Human Services. https://www.samhsa.gov